Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Sponsor: Ikena Oncology
Terminated
Sponsor strategic reasons
Other terminated trials from Ikena Oncology
- BRAF Gene Mutation · Phase PHASE1 · Sep 2025
- Advanced Solid Tumor · Phase PHASE1 · Sep 2023
- Advanced Solid Tumor · Phase PHASE1 · Aug 2023
More terminations from Ikena Oncology
Listed as NCT05228015, this PHASE1 trial focuses on Epithelioid Hemangioendothelioma (EHE) and Malignant Pleural Mesothelioma (MPM) and remains terminated or withdrawn. Sponsored by Ikena Oncology, it has been updated 9 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Dec 2024 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Aug 2023 — May 2024 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Feb 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Jul 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
First recorded
Jan 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ikena Oncology
For direct contact, visit the study record on ClinicalTrials.gov .